Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...